BLACK WEEKSViaalid −15% · komplektid −10% · muu −5%koodigaTasuta tarne Saksamaal alates €200

See leht on tõlgitud automaatselt ja võib sisaldada vigu. Kas eesti keel on sinu emakeel? Ootame hea meelega sinu tagasisidet ja parandusi.Saada tagasisidet

The Peptide Desk The Peptide Desk
Mazdutide, toote foto
GLP-1

Mazdutide

GLP-1

  • Saadetakse Saksamaalt

Tellimus

Ühiku hind - Black Weeksi ajal tasuta tarne Saksamaal alates 200 €
  • DHL koos jälgimisega
  • Diskreetne pakend

4.6 5-st Trustpilotis73 arvustust

Otsitud ka nimega: Mazdutid · LY3305677 · IBI362

Lühidalt

Mazdutide arvudes

Põhinäitajad meie leksikonist.

Täielik leksikoni artikkel
Class
GLP-1 / glucagon dual agonistoxyntomodulin analogue
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 10 mg2 sizes in the shop

Teadmised

Kõik teemal Mazdutide

Telli kohe kaasa

Mida sul sellega vaja on

Bakteriostaatiline vesi lisatakse ostukorvi automaatselt. Süstlad ja lapid ühe klõpsuga.

Insuliinisüstlad

10 tk · 5.50 €

Alkoholilapid

50 tk · 10 €

Kui palju vett?

Ühikud süstlal sinu viaali suuruse jaoks.

Ava kalkulaator →

FAQ

Korduma kippuvad küsimused

Allikad iga vastuse juurde: leksikoni artikkel

Kas sul on veel küsimusi?

Kirjuta meile, meie meeskond aitab sind.

Is Mazdutide approved?

In China, yes. The first approval came in June 2025 for long-term weight management in obesity or overweight with a related condition, type 2 diabetes followed in September 2025. Mazdutide is not approved in the EU or the USA, ChEMBL lists phase 3 as the highest phase. The information here describes the state of research and is not a recommendation for use.

How does Mazdutide differ from Tirzepatide and Retatrutide?

The receptors. Mazdutide acts on GLP-1 and glucagon, Tirzepatide on GLP-1 and GIP, Retatrutide on all three. Mazdutide is derived from the gut hormone oxyntomodulin, which naturally addresses both receptors. A running trial with a higher dose compares it directly with Tirzepatide, there are no results yet.

What did the phase 3 trials show?

In GLORY-1 weight fell by 11.0 and 14.0 percent on average after 48 weeks, on placebo it rose by 0.3 percent. In GLORY-2 with a higher dose it was 16.7 versus 1.5 percent after 60 weeks. In type 2 diabetes HbA1c fell by 1.57 and 2.15 percentage points after 24 weeks (placebo 0.14). Against dulaglutide both doses were ahead for HbA1c and weight.

How long does Mazdutide stay in the body?

In the first phase 1b study in China the half-life was between 6.3 and 16.8 days. An attached fatty acid makes this possible. That fits one dose a week, which is how all trials give Mazdutide.

How high were the doses in trials?

The highest study dose was 16 mg per week, in a phase 1 study and a phase 2 trial in the USA. There weight fell by 18.1 percent after 32 weeks, but 20 percent stopped because of side effects. All trials raise the dose in steps over weeks. The entry describes the same principle: start low and only increase while there is no noticeable effect. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In GLORY-2 53.1 percent had vomiting, 46.9 percent nausea and 39.4 percent diarrhoea (placebo 1.3, 3.2 and 6.5 percent). In GLORY-1 only 0.5 to 1.5 percent stopped because of side effects. In an early study the complaints occurred mainly in the first dose levels.

Which trials are still running?

Four of the listed phase 3 trials are not finished yet: on fatty liver versus semaglutide, on sleep apnoea, in adolescents and on high blood pressure. Phase 2 trials are running on heart failure with obesity and on fatty liver with inflammation (MASH).

Seotud

Seotud tooted